Grunenthal to present strong R&D pipeline at BIO 2012

German family-owned research-based drugmaker Grunenthal last week outlined its strong R&D pipeline of New Chemical Entities (NCE) in the areas of pain and inflammation, as well as the formulation technology platform INTAC,  which were to be at the core of the company’s presentation at BIO International Convention 2012, which starts today in Boston, USA.

“Our ultimate goal is to develop therapeutic options to improve the lives of patients suffering from pain and inflammatory diseases,” said Eric-Paul Paques, president of the newly-created Grunenthal Innovation unit and chief alliance officer.

With regard to NCEs, the focus lies on selected therapeutic areas. The later stage pipeline continues to build on the company’s leadership in developing new pain therapeutics, while in parallel a second pillar has been built in inflammation. This approach utilizes the highly interesting overlap and synergies between pain and inflammation, while at the same time establishes a unique position within the broad variety of inflammatory diseases. With its innovative tamper-resistant technology, INTAC, Grunenthal is leading the field with already two Food and Drug Administration-approved opioid products utilizing this unique technology which is designed to increase the hurdle for misuse and abuse.